KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma

Abstract

The murine sarcoma virus oncogene (KRAS) is a key gene associated with tumorigenesis and chemotherapy resistance. However, little is known about the molecular mechanisms and immune infiltration of RASs in lung adenocarcinoma. Gene Expression Profiling Interaction Analysis was used for RASs expression analysis, and Kaplan-Meier analysis was used to analyze the potential of RASs in clinical prognosis. The effect of KRAS on immune infiltration was analyzed by TIMER. In addition, the correlation between KRAS expression and molecular mechanisms was investigated by TIMER and Cancer Single-cell State Atlas (Cancer SEA). KRAS expression levels were associated with good prognosis and tumor progression. Furthermore, KRAS expression correlates with several immune cell markers and regulates tumorigenesis. KRAS expression is involved in the regulation of multiple oncogenes and tumorigenesis, especially in the prognosis and immune infiltration of lung adenocarcinoma.

Figure 1.

(A) KRAS mRNA expression in different tumor samples paired with normal tissue. In the figure, the normal group and the tumor group are shown by a violin diagram. *, **, *** indicate statistical significance and “ns” means not statistically significant. We found that the expression of KRAS was statistically significant in normal tissues and LUAD. (B) KRAS expression between tumor and non-tumor matched GTEx normal tissues. Violin plots of KRAS expression between tumor and non-tumor-matched GTEx normal tissues are shown, *, **, *** indicate statistical significance, and “ns” indicates no statistical significance. Statistically significant in LUAD.